CDK Inhibitors Upregulate BH3-Only Proteins to Sensitize Human Myeloma Cells to BH3 Mimetic Therapies
Cancer Research, 08/16/2012
Chen S et al. – The findings show that CDK inhibition potentiates pan–BH3 mimetic activity through a cooperative mechanism involving upregulation of BH3–only proteins with coordinate downregulation of their antiapoptotic counterparts. These findings have immediate implications for the clinical trial design of BH3 mimetic–based therapies that are presently being studied intensively for the treatment of diverse hematopoietic malignancies, including lethal multiple myeloma.